PT  - JOURNAL ARTICLE
AU  - de Leeuw, Marcel A.
AU  - Duval, Manuel X.
TI  - The immune profile of the gut microbiome in graft versus host disease patients
AID  - 10.1101/2020.04.08.20058198
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.08.20058198
4099  - http://medrxiv.org/content/early/2020/04/11/2020.04.08.20058198.short
4100  - http://medrxiv.org/content/early/2020/04/11/2020.04.08.20058198.full
AB  - Background Acute Graft-versus-Host Disease (aGvHD) is the main complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Gut microbiota composition has been associated with aGvHD, however, the specific composition of the intestinal ecosystem involved in the pathologic process at the time of aGvHD onset is not yet fully known.Methods A relevant series of allo-HSCT microbiome data sets were combined and reanalyzed, with focus on species level changes in the microbiota, using state-of-the-art and in part proprietary 16S analysis routines.Results Immunosuppressive conditioning was found to impact gut microbiome (GM) composition. GM composition was found highly correlated with aGvHD status at onset (R2=0.5). The species diversity, average biological safety level (BSL), gram staining balance and the strict anaerobe proportion at aGvHD onset indicate that a moderate level of gram positive strict anearobe cleansing with antibiotics reduces the risk of aGvHD. Butyrate producers were found associated with aGvHD controls, as well as the probiotic species and IL-10 inducer Bifidobacterium longum. Among species associated with mortality and aGvHD, we found Th1 and Th17 eliciting bacteria.Implications To restore the Treg/Th17 balance, probiotic supplementation with B. longum eventually combined with non-butyrigenic prebiotics and vitamin B9 is a treatment option. Simultaneous use of Van-comycin, Metronidazole, Ceftazidime and Rifaximin for GM control is a possibility, because of antibiotic resistance of B. longum.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors did not receive funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and ananlysis scripts have been made available under Github. https://github.com/GeneCreek/GvHD-manuscript